# Azilsartan in Chinese Patients With Mild and Moderate Hypertension

Study · id `cardio:ct-nct02609490` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02609490](<https://clinicaltrials.gov/study/NCT02609490>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02609490

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 304 participants.

## Technical summary

Registry record NCT02609490. Randomized; triple masking; primary purpose treatment. Start 2015-09 (actual); primary completion 2017-02 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 304 participants (enrolled count; ClinicalTrials.gov record NCT02609490, source copy `cardio:ctgov-nct02609490-2018-09-04`, retrieved 2026-10-26)
- Started: 2015-09 (actual) (ClinicalTrials.gov record NCT02609490, source copy `cardio:ctgov-nct02609490-2018-09-04`, retrieved 2026-10-26)
- Primary completion: 2017-02 (actual) (ClinicalTrials.gov record NCT02609490, source copy `cardio:ctgov-nct02609490-2018-09-04`, retrieved 2026-10-26)
- Completion: 2018-08 (actual) (ClinicalTrials.gov record NCT02609490, source copy `cardio:ctgov-nct02609490-2018-09-04`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT02609490, source copy `cardio:ctgov-nct02609490-2018-09-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02609490-2018-09-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: Azilsartan in Chinese Patients With Mild and Moderate Hypertension
- Condition: Hypertension
- Intervention (Drug): Azilsartan tablets
- Intervention (Drug): Azilsartan placebo tablets
- Intervention (Drug): Olmesartan medoxomil tablets
- Intervention (Drug): olmesartan medoxomil placebo tablets
- Lead sponsor: Lee's Pharmaceutical Limited
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Lee's Pharmaceutical Limited (`cardio:org-lee-s-pharmaceutical-limited`)

## Provenance

Content hash: dde671879650494ac230c4aa6933f0b3ae73e45ade19117d612fb5b7104bca23
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
